Neuropeptides as possible targets in sleep disorders

Bibliography

• JOUVET M: The role of monoamines and acethylcholine-containing neurons in the regulation of the sleep-waking cycle. Ergebn Physiol. (1972) 64:166-307.
   PubMedGoogle Scholar
• NISHINO S, TAHERI S, BLACK J, NOFZINGER E, MIGNOT E: The neurobiology of sleep in relation to mental illness. In: Neurobiology of Mental Illness. Charney DS NE (Ed), Oxford University Press, New York, USA (2004):1160-1179.
   Google Scholar
• AMERICAN SLEEP DISORDERS ASSOCIATION: Practice parameters for the use of stimulants in the treatment of narcolepsy. Sleep (1994) 17(4):348-351.
   PubMedGoogle Scholar
• NISHINO S, MIGNOT E: CNS Stimulants in Sleep Medicine: Basic Mechanisms and Pharmacology. In: Principles and Practice of Sleep Medicine (4th edn). Kryger MH, Roth T, Dement WC (Eds), Elsevier Saunders: Philadelphia, USA (2005):468-498.
   Google Scholar
• NISHINO S, MIGNOT E, DEMENT WC: Sedative-hypnotics. In: Textbook of Psychopharmacology. Schatzberg AF and Nemeroff CB, (Eds), American Psychiatric Press, Washington, DC, USA (2004):651-684.
   Google Scholar
• STRAND FL: Neuropeptides: Regulators of Physiological Processes. Cellular and Molecular Neuroscience Series, Stevens CF (Ed), The MIT Press, Cambridge, MA, USA (1999).
   Google Scholar
• DE LECEA L, KILDUFF TS, PEYRON C et al.: The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA (1998) 95:322-327.
   PubMed Web of Science ®Google Scholar
• SAKURAI T, AMEMIYA A, ISHII M et al.: Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell (1998) 92:573-585.
   PubMed Web of Science ®Google Scholar
• CHEMELLI RM, WILLIE JT, SINTON CM et al.: Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell (1999) 98:437-451.
   PubMed Web of Science ®Google Scholar
• LIN L, FARACO J, LI R et al.: The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell (1999) 98(3):365-376.
   PubMed Web of Science ®Google Scholar
• PEYRON C, FARACO J, ROGERS W et al.: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. (2000) 6(9):991-997.
   PubMed Web of Science ®Google Scholar
• NISHINO S, RIPLEY B, OVEREEM S et al.: Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann. Neurol. (2001) 50:381-388.
   PubMed Web of Science ®Google Scholar
• YOSHIDA Y, NISHINO S: Hypocretin/orexin tonus and vigilance control. In: The Orexin/Hypocretin System: Physiology and Pathophysiology. Nishino S and Sakurai T (Eds), Humana Press: Totowa, Japan (2006):155-173.
   Google Scholar
• PEIKIN SR, COSTENBADER CL, GARDNER JD: Actions of derivatives of cyclic nucleotides on dispersed acini from guinea pig pancreas. Discovery of a competitive antagonist of the action of cholecystokinin. J. Biol. Chem. (1979) 254(12):5321-5327.
   PubMed Web of Science ®Google Scholar
• KRAMER MS, CUTLER N, FEIGHNER J et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 281(5383):1640-1645.
   PubMed Web of Science ®Google Scholar
• KRAMER MS, WINOKUR A, KELSEY J et al.: Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology (2004) 29(2):385-392.
   PubMed Web of Science ®Google Scholar
• RANGA K, KRISHNAN R: Clinical experience with substance P receptor (NK1) antagonists in depression. J. Clin. Psychiatry (2002) 63(Suppl. 11):25-29.
   PubMedGoogle Scholar
• CHAHL LA: Tachykinins and neuropsychiatric disorders. Curr. Drug Targets (2006) 7(8):993-1003.
   Google Scholar
• PIERON H: Le Probleme Physiologique du Sommeil. Masson & Cie, Paris, France (1913).
   Google Scholar
• KRUEGER JM, OBAL FJ, FANG J, KUBOTA T, TAISHI P: The role of cytokines in physiological sleep regulation. Ann. NY Acad. Sci. (2001) 933:211-221.
   PubMed Web of Science ®Google Scholar
• MONNIER M, DUDLER L, GACHTER R, SCHOENENBERGER GA: Transport of the synthetic peptide DSIP through the blood-brain barrier in rabbit. Experientia (1977) 33(12):1609-1610.
   Google Scholar
• OBAL F Jr, KOVALZON VM, KALIKHEVICH VN et al.: Structure-activity relationship in the effects of delta-sleep-inducing peptide (DSIP) on rat sleep. Pharmacol. Biochem. Behav. (1986) 24(4):889-894.
   Google Scholar
• SCHOENENBERGER GA: Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). Eur. Neurol. (1984) 23(5):321-345.
   Google Scholar
• SUDAKOV KV, UMRYUKHIN PE, KOPLIK EV, ANOKHIN KV: Expression of the c-fos gene during emotional stress in rats: the clocking effect of delta sleep-inducing peptide. Neurosci. Behav. Physiol. (2001) 31(6):635-640.
   Google Scholar
• SILLARD R, SCHULZ-KNAPPE P, VOGEL P et al.: A novel 77-residue peptide from porcine brain contains a leucine-zipper motif and is recognized by an antiserum to delta-sleep-inducing peptide. Eur. J. Biochem. (1993) 216(2):429-436.
   Google Scholar
• SCHNEIDER-HELMERT D, GRAF M, SCHOENENBERGER GA: Synthetic delta-sleep-inducing peptide improves sleep in insomniacs. Lancet (1981) 1(8232):1256-1257.
   Google Scholar
• SCHNEIDER-HELMERT D, SCHOENENBERGER GA: Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology (1983) 9(4):197-206.
   PubMedGoogle Scholar
• BES F, HOFMAN W, SCHUUR J, VAN BOXTEL C: Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology (1992) 26(4):193-197.
   PubMed Web of Science ®Google Scholar
• MONTI JM, DEBELLIS J, ALTERWAIN P, PELLEJERO T, MONTI D: Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int. J. Clin. Pharmacol. Res. (1987) 7(2):105-110.
   Google Scholar
• RIOU F, CESPUGLIO R, JOUVET M: [Hypnogenic properties of the vasoactive intestinal polypeptide in rats]. C R Seances Acad. Sci. III (1981) 293(12):679-682.
   Google Scholar
• OBAL F Jr, OPP M, CADY AB, JOHANNSEN L, KRUEGER JM: Prolactin, vasoactive intestinal peptide, and peptide histidine methionine elicit selective increases in REM sleep in rabbits. Brain Res. (1989) 490(2):292-300.
   Google Scholar
• ROKY R, VALATX JL, PAUT-PAGANO L, JOUVET M: Hypothalamic injection of prolactin or its antibody alters the rat sleep-wake cycle. Physiol. Behav. (1994) 55(6):1015-1019.
   PubMedGoogle Scholar
• OBAL F Jr, KACSOH B, ALFOLDI P et al.: Antiserum to prolactin decreases rapid eye movement sleep (REM sleep) in the male rat. Physiol. Behav. (1992) 52(6):1063-1068.
   PubMedGoogle Scholar
• OBAL F Jr, PAYNE L, KACSOH B et al.: Involvement of prolactin in the REM sleep-promoting activity of systemic vasoactive intestinal peptide (VIP). Brain Res. (1994) 645(1-2):143-149.
   PubMed Web of Science ®Google Scholar
• MIRMIRAN M, KRUISBRINK J, BOS NP, VAN DER WERF D, BOER GJ: Decrease of rapid-eye-movement sleep in the light by intraventricular application of a VIP-antagonist in the rat. Brain Res. (1988) 458(1):192-194.
   Google Scholar
• MORIN AJ, DENOROY L, JOUVET M: Effect of paradoxical sleep deprivation on vasoactive intestinal peptide-like immunoreactivity in discrete brain areas and anterior pituitary of the rat. Brain Res. Bull. (1992) 28(5):655-661.
   Google Scholar
• WHITTAKER VP: Vasoactive intestinal polypeptide (VIP) as a cholinergic co-transmitter: some recent results. Cell Biol. Int. Rep. (1989) 13(12):1039-1051.
   Google Scholar
• BREDOW S, KACSOH B, OBAL F Jr, FANG J, KRUEGER JM: Increase of prolactin mRNA in the rat hypothalamus after intracerebroventricular injection of VIP or PACAP. Brain Res. (1994) 660(2):301-308.
   Google Scholar
• MURCK H, GULDNER J, COLLA-MULLER M et al.: VIP decelerates non-REM-REM cycles and modulates hormone secretion during sleep in men. Am. J. Physiol. (1996) 271(4 Pt 2):R905-R911.
   Google Scholar
• AHNAOU A, BASILLE M, GONZALEZ B et al.: Long-term enhancement of REM sleep by the pituitary adenylyl cyclase-activating polypeptide (PACAP) in the pontine reticular formation of the rat. Eur. J. Neurosci. (1999) 11(11):4051-4058.
   Google Scholar
• DRUCKER-COLIN RR, SPANIS CW, HUNYADI J, SASSIN JF, MCGAUGH JL: Growth hormone effects on sleep and wakefulness in the rat. Neuroendocrinology (1975) 18(1):1-8.
   Google Scholar
• STERN WC, JALOWIEC JE, SHABSHELOWITZ H, MORGANE PJ: Effects of growth hormone on sleep-waking patterns in cats. Horm. Behav. (1975) 6(2):189-196.
   Google Scholar
• TAKAHASHI Y, KIPNIS DM, DAUGHADAY WH: Growth hormone secretion during sleep. J. Clin. Invest. (1968) 47(9):2079-2090.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN SJ, WU RH, THORPY MJ et al.: Reversibility of deficient sleep entrained growth hormone secretion in a boy with achondroplasia and obstructive sleep apnea. Acta Endocrinol. (Copenh) (1987) 116(1):95-101.
   Google Scholar
• ASTROM C, PEDERSEN SA, LINDHOLM J: The influence of growth hormone on sleep in adults with growth hormone deficiency. Clin. Endocrinol. (Oxf) (1990) 33(4):495-500.
   Google Scholar
• SPIEGEL K, LEPROULT R, COLECCHIA EF et al.: Adaptation of the 24-h growth hormone profile to a state of sleep debt. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2000) 279(3):R874-R883.
   PubMed Web of Science ®Google Scholar
• ASTROM C: Interaction between sleep and growth hormone. Evaluated by manual polysomnography and automatic power spectrum analysis. Acta Neurol. Scand. (1995) 92(4):281-296.
   PubMed Web of Science ®Google Scholar
• HAJDU I, OBAL F Jr, FANG J, KRUEGER JM, ROLLO CD: Sleep of transgenic mice producing excess rat growth hormone. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2002) 282(1):R70-R76.
   Google Scholar
• EHLERS CL, REED TK, HENRIKSEN SJ: Effects of corticotropin-releasing factor and growth hormone-releasing factor on sleep and activity in rats. Neuroendocrinology (1986) 42(6):467-474.
   PubMed Web of Science ®Google Scholar
• OBAL F Jr, ALFOLDI P, CADY AB et al.: Growth hormone-releasing factor enhances sleep in rats and rabbits. Am. J. Physiol. (1988) 255(2 Pt 2):R310-R316.
   Google Scholar
• STEIGER A, GULDNER J, HEMMETER U et al.: Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology (1992) 56(4):566-573.
   PubMed Web of Science ®Google Scholar
• MARSHALL L, DERAD I, STRASBURGER CJ, FEHM HL, BORN J: A determinant factor in the efficacy of GHRH administration in promoting sleep: high peak concentration versus recurrent increasing slopes. Psychoneuroendocrinology (1999) 24(3):363-370.
   PubMedGoogle Scholar
• KERKHOFS M, VAN CAUTER E, VAN ONDERBERGEN A et al.: Sleep-promoting effects of growth hormone-releasing hormone in normal men. Am. J. Physiol. (1993) 264(4 Pt 1):E594-E598.
   Google Scholar
• OBAL F Jr, FLOYD R, KAPAS L, BODOSI B, KRUEGER JM: Effects of systemic GHRH on sleep in intact and hypophysectomized rats. Am. J. Physiol. (1996) 270(2 Pt 1):E230-E237.
   PubMedGoogle Scholar
• OBAL F Jr, KRUEGER JM: The somatotropic axis and sleep. Rev. Neurol. (Paris) (2001) 157(11 Pt 2):S12-S15.
   Google Scholar
• PERRAS B, MARSHALL L, KOHLER G, BORN J, FEHM HL: Sleep and endocrine changes after intranasal administration of growth hormone-releasing hormone in young and aged humans. Psychoneuroendocrinology (1999) 24(7):743-757.
   PubMed Web of Science ®Google Scholar
• ZHANG J, OBAL F Jr, ZHENG T et al.: Intrapreoptic microinjection of GHRH or its antagonist alters sleep in rats. J. Neurosci. (1999) 19(6):2187-2194.
   PubMed Web of Science ®Google Scholar
• BREDOW S, TAISHI P, OBEL F Jr, GUHA-THAKURTA N, KRUEGER JM: Hypothalamic growth hormone-releasing hormone mRNA varies across the day in rats. Neuroreport (1996) 7(15-17):2501-2505.
   PubMedGoogle Scholar
• GARDI J, OBAL F Jr, FANG J, ZHANG J, KRUEGER JM: Diurnal variations and sleep deprivation-induced changes in rat hypothalamic GHRH and somatostatin contents. Am. J. Physiol. (1999) 277(5 Pt 2):R1339-R1344.
   PubMed Web of Science ®Google Scholar
• TOPPILA J, ALANKO L, ASIKAINEN M et al.: Sleep deprivation increases somatostatin and growth hormone-releasing hormone messenger RNA in the rat hypothalamus. J. Sleep Res. (1997) 6(3):171-178.
   Google Scholar
• DE A, CHURCHILL L, OBAL F Jr, SIMASKO SM, KRUEGER JM: GHRH and IL1beta increase cytoplasmic Ca(2+) levels in cultured hypothalamic GABAergic neurons. Brain Res. (2002) 949(1-2):209-212.
   PubMedGoogle Scholar
• OBAL F Jr, FANG J, PAYNE LC, KRUEGER JM: Growth-hormone-releasing hormone mediates the sleep-promoting activity of interleukin-1 in rats. Neuroendocrinology (1995) 61(5):559-565.
   PubMedGoogle Scholar
• KERN W, HALDER R, AL-REDA S et al.: Systemic growth hormone does not affect human sleep. J. Clin. Endocrinol. Metab. (1993) 76(6):1428-1432.
   Google Scholar
• GARRY P, ROUSSEL B, COHEN R et al.: Diurnal administration of human growth hormone-releasing factor does not modify sleep and sleep-related growth hormone secretion in normal young men. Acta Endocrinol. (Copenh) (1985) 110(2):158-163.
   Google Scholar
• STEIGER A, HOLSBOER F: Neuropeptides and human sleep. Sleep (1997) 20(11):1038-1052.
   PubMed Web of Science ®Google Scholar
• JOHANSSON O, HOKFELT T, ELDE RP: Immunohistochemical distribution of somatostatin-like immunoreactivity in the central nervous system of the adult rat. Neuroscience (1984) 13(2):265-339.
   PubMed Web of Science ®Google Scholar
• PAYNE LC, OBAL F Jr, OPP MR, KRUEGER JM: Stimulation and inhibition of growth hormone secretion by interleukin-1 beta: the involvement of growth hormone-releasing hormone. Neuroendocrinology (1992) 56(1):118-123.
   Google Scholar
• HAVLICEK V, REZEK M, FRIESEN H: Somatostatin and thyrotropin releasing hormone: central effect on sleep and motor system. Pharmacol. Biochem. Behav. (1976) 4(4):455-459.
   PubMed Web of Science ®Google Scholar
• REZEK M, HAVLICEK V, HUGHES KR, FRIESEN H: Cortical administration of somatostatin (SRIF): effect on sleep and motor behavior. Pharmacol. Biochem. Behav. (1976) 5(1):73-77.
   PubMed Web of Science ®Google Scholar
• BERANEK L, HAJDU I, GARDI J et al.: Central administration of the somatostatin analog octreotide induces captopril-insensitive sleep responses. Am. J. Physiol. (1999) 277(5 Pt 2):R1297-R1304.
   Google Scholar
• BERANEK L, OBAL F Jr, TAISHI P et al.: Changes in rat sleep after single and repeated injections of the long-acting somatostatin analog octreotide. Am. J. Physiol. (1997) 273(4 Pt 2):R1484-R1491.
   Google Scholar
• DANGUIR J: Intracerebroventricular infusion of somatostatin selectively increases paradoxical sleep in rats. Brain Res. (1986) 367(1-2):26-30.
   Google Scholar
• DANGUIR J, DE SAINT-HILAIRE KAFI S: Reversal of desipramine-induced suppression of paradoxical sleep by a long-acting somatostatin analogue (octreotide) in rats. Neurosci. Lett. (1989) 98(2):154-158.
   Google Scholar
• TOPPILA J, NIITTYMAKI P, PORKKA-HEISKANEN T, STENBERG D: Intracerebroventricular and locus coeruleus microinjections of somatostatin antagonist decrease REM sleep in rats. Pharmacol. Biochem. Behav. (2000) 66(4):721-727.
   Google Scholar
• FRIEBOES RM, MURCK H, SCHIER T, HOLSBOER F, STEIGER A: Somatostatin impairs sleep in elderly human subjects. Neuropsychopharmacology (1997) 16(5):339-345.
   PubMedGoogle Scholar
• ZIEGENBEIN M, HELD K, KUENZEL HE et al.: The somatostatin analogue octreotide impairs sleep and decreases EEG sigma power in young male subjects. Neuropsychopharmacology (2004) 29(1):146-151.
   Google Scholar
• OBAL F Jr, ALT J, TAISHI P, GARDI J, KRUEGER JM: Sleep in mice with nonfunctional growth hormone-releasing hormone receptors. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2003) 284(1):R131-R139.
   Google Scholar
• KOJIMA M, HOSODA H, DATE Y et al.: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature (1999) 402(6762):656-660.
   PubMed Web of Science ®Google Scholar
• YAMANAKA A, BEUCKMANN CT, WILLIE JT et al.: Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron (2003) 38(5):701-713.
   PubMed Web of Science ®Google Scholar
• WEIKEL JC, WICHNIAK A, ISING M et al.: Ghrelin promotes slow-wave sleep in humans. Am. J. Physiol. Endocrinol. Metab. (2003) 284(2):E407-E415.
   PubMed Web of Science ®Google Scholar
• SCHACTHER M, PRICE PA, PARKES JD: Deprenyl in narcolepsy. Lancet (1979) 1(8120):831-832.
   Google Scholar
• SCHUESSLER P, UHR M, ISING M et al.: Nocturnal ghrelin levels – relationship to sleep EEG, the levels of growth hormone, ACTH and cortisol – and gender differences. J. Sleep Res. (2005) 14(4):329-336.
   Google Scholar
• SZENTIRMAI E, KAPAS L, KRUEGER JM: Ghrelin microinjection into forebrain sites induces wakefulness and feeding in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2006). Epub ahead of print.
   Google Scholar
• DEGLI-ESPOSTI MA, GRIFFITHS MSJ, DALY LN et al.: Characterization of 4AOHW cell line panel including new data for the 10IHW panel. Hum. Immunol. (1993) 38:3-16.
   Google Scholar
• DANGUIR J, NICOLAIDIS S: Chronic intracerebroventricular infusion of insulin causes selective increase of slow wave sleep in rats. Brain Res. (1984) 306(1-2):97-103.
   Google Scholar
• SANGIAH S, CALDWELL DF, VILLENEUVE MJ, CLANCY JJ: Sleep: sequential reduction of paradoxical (REM) and elevation of slow-wave (NREM) sleep by a non-convulsive dose of insulin in rats. Life Sci. (1982) 31(8):763-769.
   Google Scholar
• OBAL F Jr, KAPAS L, BODOSI B, KRUEGER JM: Changes in sleep in response to intracerebral injection of insulin-like growth factor-1 (IFG-1) in the rat. Sleep Res. Online (1998) 1(2):87-91.
   Google Scholar
• CRAWLEY JN, CORWIN RL: Biological actions of cholecystokinin. Peptides (1994) 15(4):731-755.
   PubMed Web of Science ®Google Scholar
• ANTIN J, GIBBS J, HOLT J, YOUNG RC, SMITH GP: Cholecystokinin elicits the complete behavioral sequence of satiety in rats. J. Comp. Physiol. Psychol. (1975) 89(7):784-790.
   PubMed Web of Science ®Google Scholar
• ROJAS-RAMIREZ JA, CRAWLEY JN, MENDELSON WB: Electroencephalographic analysis of the sleep-inducing actions of cholecystokinin. Neuropeptides (1982) 3(2):129-138.
   Google Scholar
• KAPAS L, OBAL F Jr, ALFOLDI P et al.: Effects of nocturnal intraperitoneal administration of cholecystokinin in rats: simultaneous increase in sleep, increase in EEG slow-wave activity, reduction of motor activity, suppression of eating, and decrease in brain temperature. Brain Res. (1988) 438(1-2):155-164.
   PubMed Web of Science ®Google Scholar
• FARA JW, RUBINSTEIN EH, SONNENSCHEIN RR: Visceral and behavioral responses to intraduodenal fat. Science (1969) 166(901):110-111.
   PubMedGoogle Scholar
• KAPAS L, OBAL F Jr, OPP MR, JOHANNSEN L, KRUEGER JM: Intraperitoneal injection of cholecystokinin elicits sleep in rabbits. Physiol. Behav. (1991) 50(6):1241-1244.
   PubMed Web of Science ®Google Scholar
• KAPAS L, OBAL F Jr, PENKE B, OBAL F: Cholecystokinin-octapeptide-induced hypothermia in rats: dose-effect and structure-effect relationships, effect of ambient temperature, pharmacological interactions and tolerance. Neuropharmacology (1987) 26(2-3):131-137.
   Google Scholar
• CHANG HY and KAPAS L: Selective activation of CCK-B receptors does not induce sleep and does not affect EEG slow-wave activity and brain temperature in rats. Physiol. Behav. (1997) 62(1):175-179.
   Google Scholar
• DE SAINT HILAIRE Z, ROQUES BP, NICOLAIDIS S: Effect of a highly selective central CCK-B receptor agonist: BC-264 on rat sleep. Pharmacol. Biochem. Behav. (1991) 38(3):545-548.
   Google Scholar
• WATANABE N, SAKAI T, TADA K, MASUNO J, MOROJI T: The effects of caerulein on nocturnal sleep. Prog. Neuropsychopharmacol. Biol. Psychiatry (1986) 10(6):749-754.
   Google Scholar
• LIN CW, MILLER TR: Both CCK-A and CCK-B/gastrin receptors are present on rabbit vagus nerve. Am. J. Physiol. (1992) 263(3 Pt 2):R591-R595.
   Google Scholar
• SOUTH EH, RITTER RC: Capsaicin application to central or peripheral vagal fibers attenuates CCK satiety. Peptides (1988) 9(3):601-612.
   PubMed Web of Science ®Google Scholar
• TSUJINO N, YAMANAKA A, ICHIKI K et al.: Cholecystokinin activates orexin/hypocretin neurons through the cholecystokinin A receptor. J. Neurosci. (2005) 25(32):7459-7469.
   Google Scholar
• LEE MG, HASSANI OK, JONES BE: Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J. Neurosci. (2005) 25(28):6716-6720.
   PubMed Web of Science ®Google Scholar
• PIORO EP, CUELLO AC: Distribution of nerve growth factor receptor-like immunoreactivity in the adult rat central nervous system. Effect of colchicine and correlation with the cholinergic system-II. Brainstem, cerebellum and spinal cord. Neuroscience (1990) 34(1):89-110.
   PubMedGoogle Scholar
• SERGEYEV V, HOKFELT T, HURD Y: Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. Neuroreport (1999) 10(18):3967-3970.
   PubMed Web of Science ®Google Scholar
• OTSUKA M, YOSHIOKA K: Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. (1993) 73(2):229-308.
   PubMed Web of Science ®Google Scholar
• BERRETTINI WH, RUBINOW DR, NURNBERGER JI Jr et al.: CSF substance P immunoreactivity in affective disorders. Biol. Psychiatry (1985) 20(9):965-970.
   PubMed Web of Science ®Google Scholar
• LIEB K, AHLVERS K, DANCKER K et al.: Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology (2002) 27(6):1041-1049.
   PubMed Web of Science ®Google Scholar
• ANDERSEN ML, NASCIMENTO DC, MACHADO RB et al.: Sleep disturbance induced by substance P in mice. Behav. Brain Res. (2006) 167(2):212-218.
   PubMed Web of Science ®Google Scholar
• ZHANG G, WANG L, LIU H, ZHANG J: Substance P promotes sleep in the ventrolateral preoptic area of rats. Brain Res. (2004) 1028(2):225-232.
   PubMed Web of Science ®Google Scholar
• AXELROD J, REISINE TD: Stress hormones: their interaction and regulation. Science (1984) 224(4648):452-459.
   PubMed Web of Science ®Google Scholar
• CHASTRETTE N, CESPUGLIO R, JOUVET M: Proopiomelanocortin (POMC)-derived peptides and sleep in the rat. Part 1-Hypnogenic properties of ACTH derivatives. Neuropeptides (1990) 15(2):61-74.
   Google Scholar
• CHASTRETTE N, CESPUGLIO R: Influence of proopiomelanocortin-derived peptides on the sleep-waking cycle of the rat. Neurosci. Lett. (1985) 62(3):365-370.
   Google Scholar
• CLAES SJ: Corticotropin-releasing hormone (CRH) in psychiatry: from stress to psychopathology. Ann. Med. (2004) 36(1):50-61.
   PubMed Web of Science ®Google Scholar
• OPP M, OBAL F, KRUEGER JM: Corticotropin-releasing factor attenuates interleukin 1-induced sleep and fever in rabbits. Am. J. Physiol. (1989) 257:R528-R535.
   Google Scholar
• MARROSU F, GESSA GL, GIAGHEDDU M, FRATTA W: Corticotropin-releasing factor (CRF) increases paradoxical sleep (PS) rebound in PS-deprived rats. Brain Res. (1990) 515(1-2):315-318.
   PubMedGoogle Scholar
• CHANG FC and OPP MR: Role of corticotropin-releasing hormone in stressor-induced alterations of sleep in rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2002) 283(2):R400-R407.
   Google Scholar
• GRIFFITHS EC, BENNETT GW: Clinical applications of thyrotropin-releasing hormone. Clin. Sci. (1987) 73:449-457.
   Web of Science ®Google Scholar
• WINOKUR A, MANAKER S, KRIEDER M: TRH and TRH receptors in the spinal cord. Ann NY Acad. Sci. USA (1989) 553:314-324.
   Google Scholar
• GERSHENGORN MC: Thyrotropin-releasing hormone-mechanism of calcium-mediated stimulation of prolactin secretion. Recent Prog. Horm. Res. (1985) 41:607-646.
   Google Scholar
• PRANGE AJ Jr, LARA PP, WILSON IC, ALLTOP LB, BREESE GR: Effects of thyrotropin-releasing hormone in depression. Lancet (1972) 2(7785):999-1002.
   PubMed Web of Science ®Google Scholar
• FADEN AI: Neuropeptide and central nervous system injury: clinical implications. Arch. Neurol. (1986) 45:501-504.
   Google Scholar
• SOBUE I, TAKAYANAGI T, NAKANISHI T et al.: Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations. J. Neuro. Sci. (1983) 61:235-248.
   PubMed Web of Science ®Google Scholar
• ENGEL WK, SIDDIQUE T, NICOLOFF J: Effect on weakness and spasticity in amyotrophic lateral sclerosis of thyrotropin-releasing hormone. Lancet (1983) 2:73-75.
   PubMed Web of Science ®Google Scholar
• REDDING TW, SCHALLY AV: On the half life of thyrotropin-releasing hormone in rats. Neuroendocrinology (1972) 9:250-256.
   PubMed Web of Science ®Google Scholar
• HEMMETER U, ROTHE B, GULDNER J, HOLSBOER F, STEIGER A: Effects of thyrotropin-releasing hormone on the sleep EEG and nocturnal hormone secretion in male volunteers. Neuropsychobiology (1998) 38(1):25-31.
   PubMed Web of Science ®Google Scholar
• NISHINO S, ARRIGONI J, SHELTON J et al.: Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J. Neurosci. (1997) 17:6401-6408.
   PubMed Web of Science ®Google Scholar
• RIEHL J, HONDA K, KWAN M et al.: Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy. Neuropsychopharmacology (2000) 23(1):34-45.
   PubMed Web of Science ®Google Scholar
• BROBERGER C, MCCORMICK DA: Excitatory effects of thyrotropin-releasing hormone in the thalamus. J. Neurosci. (2005) 25(7):1664-1673.
   PubMed Web of Science ®Google Scholar
• GAUS SE, STRECKER RE, TATE BA, PARKER RA, SAPER CB: Ventrolateral preoptic nucleus contains sleep-active, galaninergic neurons in multiple mammalian species. Neuroscience (2002) 115(1):285-294.
   PubMed Web of Science ®Google Scholar
• SHERIN J, SHIROMANI P, MCCARLEY R, SAPER C: Activation of ventrolateral preoptic neurons during sleep. Science (1996) 271:216-220.
   PubMed Web of Science ®Google Scholar
• DAVIS TM, BURRIN JM, BLOOM SR: Growth hormone (GH) release in response to GH-releasing hormone in man is 3-fold enhanced by galanin. J. Clin. Endocrinol. Metab. (1987) 65(6):1248-1252.
   Google Scholar
• SHERIN JE, ELMQUIST JK, TORREALBA F, SAPER CB: Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J. Neurosci. (1998) 18(12):4705-4721.
   PubMed Web of Science ®Google Scholar
• TOPPILA J, STENBERG D, ALANKO L et al.: REM sleep deprivation induces galanin gene expression in the rat brain. Neurosci. Lett. (1995) 183(3):171-174.
   PubMedGoogle Scholar
• FUJIHARA H, SERINO R, UETA Y, SEI H, MORITA Y: Six-hour selective REM sleep deprivation increases the expression of the galanin gene in the hypothalamus of rats. Brain Res. Mol. Brain Res. (2003) 119(2):152-159.
   Google Scholar
• SEUTIN V, VERBANCK P, MASSOTTE L, DRESSE A: Galanin decreases the activity of locus coeruleus neurons in vitro. Eur. J. Pharmacol. (1989) 164(2):373-376.
   Google Scholar
• SEVCIK J, FINTA EP, ILLES P: Galanin receptors inhibit the spontaneous firing of locus coeruleus neurones and interact with mu-opioid receptors. Eur. J. Pharmacol. (1993) 230(2):223-230.
   PubMed Web of Science ®Google Scholar
• MURCK H, ANTONIJEVIC IA, FRIEBOES RM et al.: Galanin has REM-sleep deprivation-like effects on the sleep EEG in healthy young men. J. Psychiatr. Res. (1999) 33(3):225-232.
   Google Scholar
• SPIER AD and DE LECEA L: Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. Brain Res. Brain Res. Rev. (2000) 33(2-3):228-241.
   PubMed Web of Science ®Google Scholar
• DE LECEA L, RUIZ-LOZANO P, DANIELSON PE et al.: Cloning, mRNA expression, and chromosomal mapping of mouse and human preprocortistatin. Genomics (1997) 42(3):499-506.
   Google Scholar
• DE LECEA L, DEL RIO JA, CRIADO JR et al.: Cortistatin is expressed in a distinct subset of cortical interneurons. J. Neurosci. (1997) 17(15):5868-5880.
   PubMed Web of Science ®Google Scholar
• DE LECEA L, CRIADO JR, PROSPERO-GARCIA O et al.: A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature (1996) 381(6579):242-245.
   PubMed Web of Science ®Google Scholar
• VASILAKI A, LANNEAU C, DOURNAUD P et al.: Cortistatin affects glutamate sensitivity in mouse hypothalamic neurons through activation of sst2 somatostatin receptor subtype. Neuroscience (1999) 88(2):359-364.
   Google Scholar
• DEGHENGHI R, PAPOTTI M, GHIGO E, MUCCIOLI G: Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland. J. Endocrinol. Invest. (2001) 24(1):RC1-RC3.
   PubMed Web of Science ®Google Scholar
• XU YL, REINSCHEID RK, HUITRON-RESENDIZ S et al.: Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron (2004) 43(4):487-497.
   PubMed Web of Science ®Google Scholar
• HUITRON-RESENDIZ S, KRISTENSEN MP, SANCHEZ-ALAVEZ M et al.: Urotensin II modulates rapid eye movement sleep through activation of brainstem cholinergic neurons. J. Neurosci. (2005) 25(23):5465-5474.
   Google Scholar
• REINSCHEID RK, XU YL, CIVELLI O: Neuropeptide s: a new player in the modulation of arousal and anxiety. Mol. Interv. (2005) 5(1):42-46.
   Google Scholar
• SAKURAI T: Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. Sleep Med. Rev. (2005) 9(4):231-241.
   PubMed Web of Science ®Google Scholar
• PEYRON C, TIGHE DK, VAN DEN POL AN et al.: Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. (1998) 18(23):9996-10015.
   PubMed Web of Science ®Google Scholar
• BROWN RE, STEVENS DR, HAAS HL: The physiology of brain histamine. Prog. Neurobiol. (2001) 63(6):637-672.
   PubMed Web of Science ®Google Scholar
• ERIKSSON KS, SERGEEVA O, BROWN RE, HAAS HL: Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J. Neurosci. (2001) 21(23):9273-9279.
   PubMed Web of Science ®Google Scholar
• KOROTKOVA TM, SERGEEVA OA, ERIKSSON KS, HAAS HL, BROWN RE: Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. J. Neurosci. (2003) 23(1):7-11.
   PubMed Web of Science ®Google Scholar
• HAGAN JJ, LESLIE RA, PATEL S et al.: Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl. Acad. Sci. USA (1999) 96(19):10911-10916.
   PubMed Web of Science ®Google Scholar
• FUJIKI N, RIPLEY B, YOSHIDA Y, MIGNOT E, NISHINO S: Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin ligand deficient narcoleptic dog. Sleep (2003) 6(8):953-959.
   Google Scholar
• ESPANA RA, PLAHN S, BERRIDGE CW: Circadian-dependent and circadian-independent behavioral actions of hypocretin/orexin. Brain Res. (2002) 943(2):224-236.
   Google Scholar
• IDA T, NAKAHARA K, KATAYAMA T, MURAKAMI N, NAKAZATO M: Effect of lateral cerebroventricular injection of the appetite-stimulating neuropeptide, orexin and neuropeptide Y, on the various behavioral activities of rats. Brain Res. (1999) 821:526-529.
   PubMed Web of Science ®Google Scholar
• EDWARDS CM, ABUSNANA S, SUNTER D et al.: The effect of the orexins on food intake: comparison with neuropeptide Y, melanin-concentrating hormone and galanin. J. Endocrinol. (1999) 160(3):R7-R12.
   Google Scholar
• YOSHIDA Y, FUJIKI N, NAKAJIMA T et al.: Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur. J. Neurosci. (2001) 14(7):1075-1081.
   PubMed Web of Science ®Google Scholar
• TERAO A, PEYRON C, DING J et al.: Prepro-hypocretin (prepro-orexin) expression is unaffected by short- term sleep deprivation in rats and mice. Sleep (2000) 23(7):867-874.
   Google Scholar
• MILEYKOVSKIY BY, KIYASHCHENKO LI, SIEGEL JM: Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron (2005) 46(5):787-798.
   PubMed Web of Science ®Google Scholar
• YAMANAKA A, MURAKI Y, TSUJINO N, GOTO K, SAKURAI T: Regulation of orexin neurons by the monoaminergic and cholinergic systems. Biochem. Biophys. Res. Commun. (2003) 303(1):120-129.
   Google Scholar
• BAYER L, COLARD C, NGUYEN NU et al.: Alteration of the expression of the hypocretin (orexin) gene by 2-deoxyglucose in the rat lateral hypothalamic area. Neuroreport (2000) 11(3):531-533.
   Google Scholar
• QU D, LUDWIG DS, GAMMELTOFT S et al.: A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature (1996) 380(6571):243-247.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO Y, UETA Y, DATE Y et al.: Down regulation of the prepro-orexin gene expression in genetically obese mice. Mol. Brain Res. (1999) 65(1):14-22.
   PubMedGoogle Scholar
• MODIRROUSTA M, MAINVILLE L, JONES BE: Orexin and MCH neurons express c-Fos differently after sleep deprivation versus recovery and bear different adrenergic receptors. Eur. J. Neurosci. (2005) 21(10):2807-2816.
   Google Scholar
• VERRET L, GOUTAGNY R, FORT P et al.: A role of melanin-concentrating hormone producing neurons in the central regulation of paradoxical sleep. BMC Neurosci. (2003) 4(1):19.
   PubMed Web of Science ®Google Scholar
• BAYER L, EGGERMANN E, SERAFIN M et al.: Opposite effects of noradrenaline and acetylcholine upon hypocretin/orexin versus melanin concentrating hormone neurons in rat hypothalamic slices. Neuroscience (2005) 130(4):807-811.
   PubMed Web of Science ®Google Scholar
• WAHLESTEDT C, REIS DJ: Neuropeptide Y-related peptides and their receptors-are the receptors potential therapeutic drug targets? Ann. Rev. Pharmacol. Toxicol. (1993) 33:309-352.
   PubMedGoogle Scholar
• CABERLOTTO L, FUXE K, HURD YL: Characterization of NPY mRNA-expressing cells in the human brain: co-localization with Y2 but not Y1 mRNA in the cerebral cortex, hippocampus, amygdala, and striatum. J. Chem. Neuroanat. (2000) 20(3-4):327-337.
   Google Scholar
• ZINI I, MERLO PICH E, FUXE K et al.: Actions of centrally administered neuropeptide Y on EEG activity in different rat strains and in different phases of their circadian cycle. Acta Physiol. Scand. (1984) 122(1):71-77.
   PubMedGoogle Scholar
• EHLERS CL, SOMES C, LOPEZ A, KIRBY D, RIVIER JE: Electrophysiological actions of neuropeptide Y and its analogs: new measures for anxiolytic therapy? Neuropsychopharmacology (1997) 17(1):34-43.
   PubMedGoogle Scholar
• SZENTIRMAI E, KRUEGER JM: Central administration of neuropeptide Y induces wakefulness in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2006). Epub ahead of print.
   Google Scholar
• AKANMU MA, UKPONMWAN OE, KATAYAMA Y, HONDA K: Neuropeptide-Y Y2-receptor agonist, PYY3-36 promotes non-rapid eye movement sleep in rat. Neurosci. Res. (2006) 54(3):165-170.
   Google Scholar
• ANTONIJEVIC IA, MURCK H, BOHLHALTER S et al.: Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology (2000) 39(8):1474-1481.
   PubMedGoogle Scholar
• HELD K, ANTONIJEVIC I, MURCK H, KUENZEL H, STEIGER A: Neuropeptide Y (NPY) shortens sleep latency but does not suppress ACTH and cortisol in depressed patients and normal controls. Psychoneuroendocrinology (2006) 31(1):100-107.
   PubMedGoogle Scholar
• NISHINO S, OKURA M, MIGNOT E: Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med. Rev. (2000) 4(1):57-99.
   PubMed Web of Science ®Google Scholar
• BROUGHTON R, DUNHAM W, NEWMAN J et al.: Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched control. Electroenceph. Clin. Neurophysiol. (1988) 70:473-481.
   PubMedGoogle Scholar
• ALDRICH MS, CHERVIN RD, MALOW BA: Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep (1997) 20(8):620-629.
   PubMed Web of Science ®Google Scholar
• FUKUDA K, MIYASITA A, INUGAMI M, ISHIHARA K: High prevalence of isolated sleep paralysis: Kanashibari phenomenon in Japan. Sleep (1987) 10(3):279-286.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI T, MIYASITA A, SASAKI Y, INUGAMI M, FUKUDA K: Isolated sleep paralysis elicited by sleep interruption. Sleep (1992) 15(3):217-225.
   PubMed Web of Science ®Google Scholar
• NISHINO S, RIPLEY B, OVEREEM S, LAMMERS GJ, MIGNOT E: Hypocretin (orexin) deficiency in human narcolepsy. Lancet (2000) 355(9197):39-40.
   PubMed Web of Science ®Google Scholar
• NISHINO S, KANBAYASHI T: Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications In the hypothalamic hypocretin/orexin system. Sleep Med. Rev. (2005) 9(4):269-310.
   PubMed Web of Science ®Google Scholar
• NISHINO S and MIGNOT E: Pharmacological aspects of human and canine narcolepsy. Prog. Neurobiol. (1997) 52(1):27-78.
   PubMed Web of Science ®Google Scholar
• MIGNOT E: Pathophysiology of Narcolepsy, In: Principles and Practice of Sleep Medicine. Kryger MH, Roth T, Dement WC, Roth T (Eds)., W.B. Saunders Company, Philadelphia. USA (2000):663-675.
   Google Scholar
• MITLER MM, ALDRICH MS, KOOB GF, ZARCONE VP: Narcolepsy and its treatment with stimulants. Sleep (1994) 17(4):352-371.
   PubMed Web of Science ®Google Scholar
• WISOR JP, NISHINO S, SORA I et al.: Dopaminergic role in stimulant-induced wakefulness. J. Neurosci. (2001) 21(5):1787-1794.
   PubMed Web of Science ®Google Scholar
• NISHINO S, MAO J, SAMPATHKUMARAN R, SHELTON J, MIGNOT E: Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res. Online (1998) 1:49-61.
   PubMedGoogle Scholar
• BABCOCK DA, NARVER EL, DEMENT WC, MITLER MM: Effects of imipramine, chlorimipramine, and fluoxetine on cataplexy in dogs. Pharmacol. Biochem. Behav. (1976) 5:599-602.
   PubMed Web of Science ®Google Scholar
• FOUTZ AS, DELASHAW JB, GUILLEMINAULT C, DEMENT WC: Monoaminergic mechanisms and experimental cataplexy. Ann. Neurol. (1981) 10:369-376.
   PubMed Web of Science ®Google Scholar
• YAMANAKA A, TSUJINO N, FUNAHASHI H et al.: Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem. Biophys. Res. Commun. (2002) 290(4):1237-1245.
   PubMed Web of Science ®Google Scholar
• KIYASHCHENKO LI, MILEYKOVSKIY BY, LAI YY, SIEGEL JM: Increased and decreased muscle tone with orexin (hypocretin) microinjections in the locus coeruleus and pontine inhibitory area. J. Neurophysiol. (2001) 85(5):2008-2016.
   PubMed Web of Science ®Google Scholar
• NAMBU T, SAKURAI T, MIZUKAMI K et al.: Distribution of orexin neurons in the adult rat brain. Brain Res. (1999) 827:243-260.
   PubMed Web of Science ®Google Scholar
• HORVATH TL, PEYRON C, DIANO S et al.: Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J. Comp. Neurol. (1999) 415(2):145-159.
   PubMed Web of Science ®Google Scholar
• TAHERI S, ZEITZER JM, MIGNOT E: The role of hypocretins (orexins) in sleep regulation and narcolepsy. Ann. Rev. Neurosci. (2002) 25:283-313.
   PubMed Web of Science ®Google Scholar
• HARA J, BEUCKMANN CT, NAMBU T et al.: Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron (2001) 30(2):345-354.
   PubMed Web of Science ®Google Scholar
• MIEDA M, WILLIE JT, HARA J et al.: Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc. Natl. Acad. Sci. USA (2004) 101(13):4649-4654.
   PubMed Web of Science ®Google Scholar
• FUJIKI N, YOSHIDA Y, RIPLEY B, MIGNOT E, NISHINO S: Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep (2003) 26(8):953-959.
   PubMed Web of Science ®Google Scholar
• TONOKURA M, FUJITA K, MOROZUMI M et al.: Narcolepsy in a hypocretin/orexin-deficient chihuahua. Vet. Rec. (2003) 152(25):776-779.
   Google Scholar
• RIPLEY B, FUJIKI N, OKURA M, MIGNOT E, NISHINO S: Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol. Dis. (2001) 8(3):525-534.
   PubMed Web of Science ®Google Scholar
• SCHATZBERG SJ, CUTTER-SCHATZBERG K, NYDAM D et al.: The effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy. J. Vet. Internal Med. (2004) 18(4):586-588.
   PubMed Web of Science ®Google Scholar
• LATERRA J, GOLDSTEIN GW: Ventricular organization of cerebrospinal fluid: Bllod-brain barrier, brain edema, and hydrocephalus. In: Principles of Neural Science. Kandel ER, Schwartz JH, Jessell TM (Eds), McGraw-Hill: New York, USA (2004).
   Google Scholar
• JOHANSON CE: Ventricles and cerebrospinal Fluid. In: Neuroscience in Medicine. PMC (Ed), JB Lippincott Company, Philadelphia, USA (1995):171-196.
   Google Scholar
• BRIGHTMAN MW: Morphology of blood-brain interfaces. Exp. Eye Res. (1977) 25(Suppl.):1-25.
   PubMed Web of Science ®Google Scholar
• BEGLEY DJ, BRIGHTMAN MW: Structural and functional aspects of the blood-brain barrier. Prog. Drug Res. (2003) 61:39-78.
   PubMedGoogle Scholar
• PROKAI-TATRAI K, PROKAI L: Modifying peptide properties by prodrug design for enhanced transport into the CNS. Prog. Drug Res. (2003) 61:155-188.
   PubMedGoogle Scholar
• GRONDIN R, ZHANG Z, AI Y, GASH DM, GERHARDT GA: Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases. Prog. Drug Res. (2003) 61:101-123.
   PubMedGoogle Scholar
• PROKAI L: Peptide drug delivery into the central nervous system. Prog. Drug Res. (1998) 51:95-131.
   PubMedGoogle Scholar
• KASTIN AJ, AKERSTROM V: Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J. Pharmacol. Exp. Ther. (1999) 289(1):219-223.
   PubMed Web of Science ®Google Scholar
• YOSHIDA Y, FUJIKI N, MAKI RA, SCHWARZ D, NISHINO S: Differential kinetics of hypocretins in the cerebrospinal fluid after intracerebroventricular administration in rats. Neurosci. Lett. (2003) 346(3):182-186.
   PubMed Web of Science ®Google Scholar
• ASAHI S, EGASHIRA S, MATSUDA M et al.: Development of an orexin-2 receptor selective agonist, [Ala(11), D-Leu(15)]orexin-B. Bioorg. Med. Chem. Lett. (2003) 13(1):111-113.
   PubMed Web of Science ®Google Scholar
• ASAHI S, EGASHIRA S, MATSUDA M et al.: Structure-activity relationship stidies on the novel neuropeptide orexin. In: The Japanese Peptide Society (2000).
   Google Scholar
• DARKER JG, PORTER RA, EGGLESTON DS et al.: Structure-activity analysis of truncated orexin-A analogues at the orexin-1 receptor. Bioorg. Med. Chem. Lett. (2001) 11(5):737-740.
   PubMed Web of Science ®Google Scholar
• LANG M, SOLL RM, DURRENBERGER F, DAUTZENBERG FM, BECK-SICKINGER AG: Structure-activity studies of orexin a and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands. J. Med. Chem. (2004) 47(5):1153-1160.
   PubMed Web of Science ®Google Scholar
• WHEATLEY M, HAWTIN SR, WESLEY VJ et al.: Agonist binding to peptide hormone receptors. Biochem. Soc. Trans. (2003) 31(Pt 1):35-39.
   Google Scholar
• CROSTON GE, OLSSON R, CURRIER EA et al.: Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor:3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954). J. Med. Chem. (2002) 45(23):4950-4953.
   Google Scholar
• ZAVERI N: Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci. (2003) 73(6):663-678.
   PubMed Web of Science ®Google Scholar
• CHACKALAMANNIL S, DOLLER D, EAGEN K et al.: Potent, low molecular weight thrombin receptor antagonists. Bioorg. Med. Chem. Lett. (2001) 11(21):2851-2853.
   PubMed Web of Science ®Google Scholar
• SAAR K, MAZARATI AM, MAHLAPUU R et al.: Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc. Natl. Acad. Sci. USA (2002) 99(10):7136-7141.
   PubMed Web of Science ®Google Scholar
• FREY II WH, LIU J, CHEN X et al.: Delivery of 125I-NGF to the brain via the olfactory route. Drug Deliv. (1997) 4:87-92.
   Web of Science ®Google Scholar
• FREY II WH: Intranasal delivery: bypassing the blood-brain barrier to deliver therapeutic agents to the brain and spinal cord. Drug Deliv. Technol. (2002) 2(5):46-49.
   Google Scholar
• THORNE RG, FREY WH II: Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin. Pharmacokinet. (2001) 40(12):907-946.
   PubMed Web of Science ®Google Scholar
• CAPSONI S, GIANNOTTA S, CATTANEO A: Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc. Natl. Acad. Sci. USA (2002) 99(19):12432-12437.
   PubMed Web of Science ®Google Scholar
• JIN K, XIE L, CHILDS J et al.: Cerebral neurogenesis is induced by intranasal administration of growth factors. Ann. Neurol. (2003) 53(3):405-409.
   PubMed Web of Science ®Google Scholar
• BORN J, LANGE T, KERN W et al.: Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. (2002) 5(6):514-516.
   PubMed Web of Science ®Google Scholar
• KWON MO, HERRLING P: List of drugs in development for neurodegenerative diseases. Update june 2006. Neurodegener. Dis. (2006) 3(3):148-186.
   Google Scholar
• SHEMAN TG, AKIL H, WATSON SJ: The Molecular Biology of Neuropeptide. Discussion in Neuroscience. Vol. 6. Amsterdam: Elsevier. (1989).
   Google Scholar
• SAKURAI T: Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. Sleep Med. Rev. (2005) 9(4):231-241.
   PubMed Web of Science ®Google Scholar